Invest in Lifesaving Cancer Detection
Saving Lives Starts Here
Cizzle Bio is transforming cancer detection with leading-edge biomarker blood tests that identify disease at its earliest and most treatable stage.
Our proprietary tests, CIZ1B for lung cancer and DEX-G2 for gastric cancer, are based on decades of research and engineered for real-world clinical integration. These innovations offer exceptional accuracy, cost-effectiveness, and scale—poised to change the diagnostic landscape for two of world’s deadliest cancers.
With strong clinical momentum, a capital-efficient model, and global market opportunities, Cizzle Bio is uniquely positioned for accelerated growth and meaningful impact.
Why Invest in Cizzle Bio?
Breakthrough Science
Proprietary biomarkers developed from decades of research at the University of York and City of Hope Comprehensive Cancer Center.
Early-Mover Advantage
Focused on high-burden cancers with no widely adopted early detection tests.
Proven Leadership
CEO Bill Behnke and the leadership team brings decades of healthcare innovation and strategic growth experience.
Scalable Business Model
Lean operations with U.S. lab partnerships and global commercialization underway.
Ready to Join Us?
Be part of our mission to detect cancer early and save lives. Learn more about our investment opportunity and how you can help bring lifesaving innovations to market.
FOR INVESTMENTS OF $100,000 OR MORE
Email our CEO, Bill Behnke, to schedule a call.
FOR INVESTMENTS UNDER $100,000
Please visit out investor page.
Help Advance the Future of Early Cancer Detection
Together, we can advance the future of early cancer detection.